Logo image of ADCT

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

USA - NYSE:ADCT - CH0499880968 - Common Stock

3.42 USD
+0.03 (+0.88%)
Last: 9/19/2025, 7:41:05 PM
3.42 USD
0 (0%)
After Hours: 9/19/2025, 7:41:05 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADCT. ADCT was compared to 540 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. ADCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADCT had negative earnings in the past year.
In the past year ADCT has reported a negative cash flow from operations.
In the past 5 years ADCT always reported negative net income.
In the past 5 years ADCT always reported negative operating cash flow.
ADCT Yearly Net Income VS EBIT VS OCF VS FCFADCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of ADCT (-52.85%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.85%
ROE N/A
ROIC N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADCT Yearly ROA, ROE, ROICADCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

The Gross Margin of ADCT (93.37%) is better than 92.96% of its industry peers.
In the last couple of years the Gross Margin of ADCT has declined.
The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
ADCT Yearly Profit, Operating, Gross MarginsADCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADCT has more shares outstanding
The number of shares outstanding for ADCT has been increased compared to 5 years ago.
Compared to 1 year ago, ADCT has a worse debt to assets ratio.
ADCT Yearly Shares OutstandingADCT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADCT Yearly Total Debt VS Total AssetsADCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.60, we must say that ADCT is in the distress zone and has some risk of bankruptcy.
ADCT has a Altman-Z score of -6.60. This is in the lower half of the industry: ADCT underperforms 66.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.6
ROIC/WACCN/A
WACC4.95%
ADCT Yearly LT Debt VS Equity VS FCFADCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ADCT has a Current Ratio of 4.93. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.93, ADCT is in line with its industry, outperforming 53.52% of the companies in the same industry.
ADCT has a Quick Ratio of 4.66. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.66, ADCT perfoms like the industry average, outperforming 52.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 4.66
ADCT Yearly Current Assets VS Current LiabilitesADCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.14% over the past year.
Looking at the last year, ADCT shows a very negative growth in Revenue. The Revenue has decreased by -35.37% in the last year.
ADCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.48% yearly.
EPS 1Y (TTM)43.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-35.37%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%8.21%

3.2 Future

The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
Based on estimates for the next years, ADCT will show a very strong growth in Revenue. The Revenue will grow by 33.94% on average per year.
EPS Next Y6.78%
EPS Next 2Y8.81%
EPS Next 3Y12.92%
EPS Next 5YN/A
Revenue Next Year7.88%
Revenue Next 2Y7.05%
Revenue Next 3Y25.44%
Revenue Next 5Y33.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADCT Yearly Revenue VS EstimatesADCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ADCT Yearly EPS VS EstimatesADCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADCT. In the last year negative earnings were reported.
Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADCT Price Earnings VS Forward Price EarningsADCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADCT Per share dataADCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ADCT's earnings are expected to grow with 12.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.81%
EPS Next 3Y12.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADC THERAPEUTICS SA

NYSE:ADCT (9/19/2025, 7:41:05 PM)

After market: 3.42 0 (0%)

3.42

+0.03 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-05 2025-11-05/amc
Inst Owners60.89%
Inst Owner Change24.39%
Ins Owners6.59%
Ins Owner Change35.38%
Market Cap384.75M
Analysts86.67
Price Target8.41 (145.91%)
Short Float %4.87%
Short Ratio6.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)12.49%
Max EPS beat(2)21.4%
EPS beat(4)3
Avg EPS beat(4)15.15%
Min EPS beat(4)-4.24%
Max EPS beat(4)30.94%
EPS beat(8)6
Avg EPS beat(8)-1.26%
EPS beat(12)6
Avg EPS beat(12)-10.49%
EPS beat(16)10
Avg EPS beat(16)0.13%
Revenue beat(2)2
Avg Revenue beat(2)15.46%
Min Revenue beat(2)3.41%
Max Revenue beat(2)27.51%
Revenue beat(4)2
Avg Revenue beat(4)4.05%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)27.51%
Revenue beat(8)3
Avg Revenue beat(8)0.74%
Revenue beat(12)5
Avg Revenue beat(12)0.65%
Revenue beat(16)8
Avg Revenue beat(16)7.74%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.84%
EPS NQ rev (3m)17.29%
EPS NY rev (1m)-20.06%
EPS NY rev (3m)-3.52%
Revenue NQ rev (1m)0.57%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)1.21%
Revenue NY rev (3m)3.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.98
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.69
BVpS-1.77
TBVpS-1.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.37%
FCFM N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.61%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 4.66
Altman-Z -6.6
F-Score2
WACC4.95%
ROIC/WACCN/A
Cap/Depr(3y)74.54%
Cap/Depr(5y)119.38%
Cap/Sales(3y)2.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y6.78%
EPS Next 2Y8.81%
EPS Next 3Y12.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-35.37%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%8.21%
Revenue Next Year7.88%
Revenue Next 2Y7.05%
Revenue Next 3Y25.44%
Revenue Next 5Y33.94%
EBIT growth 1Y51.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.43%
OCF growth 3YN/A
OCF growth 5YN/A